Adverum Biotechnologies I...

NASDAQ: ADVM · Real-Time Price · USD
2.21
-0.02 (-0.90%)
At close: May 23, 2025, 3:59 PM
2.21
0.00%
After-hours: May 23, 2025, 04:04 PM EDT

Company Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.

Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.

Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.

The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.

Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc. logo
Country United States
IPO Date Jul 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Dr. Laurent Fischer

Contact Details

Address:
800 Saginaw Drive
Redwood City, California
United States
Website https://www.adverum.com

Stock Details

Ticker Symbol ADVM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501756
CUSIP Number 00773U108
ISIN Number US00773U1088
Employer ID 20-5258327
SIC Code 2836

Key Executives

Name Position
Dr. Laurent Fischer President, Chief Executive Officer & Director
Dena House Chief People Officer
Dr. R. Andrew Ramelmeier Ph.D. Chief Technology Officer
Kishor Peter Soparkar J.D. Chief Operating Officer
Linda M. Rubinstein M.A. Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Aneta Ferguson General Counsel
Carla Fiankan Senior Vice President of Regulatory Affairs
Dr. Rabia Gurses Ozden M.D. Chief Medical Officer
Dr. Romuald Corbau Ph.D. Chief Scientific Officer
Dr. Setareh Seyedkazemi Pharm.D. Chief Development Officer

Latest SEC Filings

Date Type Title
May 20, 2025 SCHEDULE 13D Filing
May 16, 2025 4 Filing
May 16, 2025 4 Filing
May 16, 2025 4 Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 14, 2025 10-Q Quarterly Report
May 14, 2025 8-K Current Report
May 06, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Filing